Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Industry News

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

September 01, 2015

News Industry News

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

July 07, 2015

News Industry News

Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease

May 19, 2015

News Industry News

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

September 15, 2014

News Industry News

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

September 14, 2014

News Industry News

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

August 11, 2014

News Industry News

Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

May 23, 2014

News Industry News

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

October 31, 2013

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Industry News

Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent

December 07, 2011

News Industry News

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

November 08, 2011

Advertisement

Abbott Announces Positive Results Of Its Naturally Dissolving Stent From Absorb Japan Study

Novartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril-valsartan)

Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease

Abbott Initiates ABSORB IV Trial to Evaluate Quality of Life and Cost Savings of Dissolving Heart Device

ABSORB II Study Shows Abbott's Dissolving Heart Device Comparable to the World's Leading Heart Stent

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

Abbott Initiates Clinical Trial to Evaluate the Absorb™ Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent

Cangrelor provides effective maintenance of platelet inhibition without major bleeding for patients who require bypass surgery

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content